Chongqing Pharscin Pharmaceutical Co Ltd Market Cap ($788.90 Million)
Market Cap & Net Worth: Chongqing Pharscin Pharmaceutical Co Ltd (002907)
Chongqing Pharscin Pharmaceutical Co Ltd market cap. Chongqing Pharscin Pharmaceutical Co Ltd (SHE:002907) has a market capitalization of $788.90 Million (CN¥5.39 Billion) as of November 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #9581 globally and #2375 in its home market, demonstrating a -5.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chongqing Pharscin Pharmaceutical Co Ltd's stock price CN¥12.91 by its total outstanding shares 417596314 (417.60 Million). Also see cash flow conversion of Chongqing Pharscin Pharmaceutical Co Ltd for how efficiently the company converts equity into cash flow.
Chongqing Pharscin Pharmaceutical Co Ltd Market Cap History (2017–2026)
Chongqing Pharscin Pharmaceutical Co Ltd market cap history from 2017 to 2026. Data shows growth from $1.12 Billion to $788.90 Million (8.13% CAGR). Check latest Chongqing Pharscin Pharmaceutical Co Ltd stock price today for real-time trading data and today's change.
Chongqing Pharscin Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chongqing Pharscin Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 002907 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.03x
Chongqing Pharscin Pharmaceutical Co Ltd's market cap is 1.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
10.35x
Chongqing Pharscin Pharmaceutical Co Ltd's market cap is 10.35 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.12 Billion | $592.10 Million | $111.99 Million | 1.90x | 10.04x |
| 2018 | $1.13 Billion | $703.41 Million | $137.37 Million | 1.60x | 8.20x |
| 2019 | $998.34 Million | $842.06 Million | $169.75 Million | 1.19x | 5.88x |
| 2020 | $806.21 Million | $882.47 Million | $119.19 Million | 0.91x | 6.76x |
| 2021 | $1.09 Billion | $846.14 Million | $91.78 Million | 1.28x | 11.84x |
| 2022 | $1.23 Billion | $785.18 Million | $98.40 Million | 1.57x | 12.50x |
| 2023 | $937.89 Million | $691.54 Million | $32.70 Million | 1.36x | 28.68x |
| 2024 | $794.40 Million | $774.82 Million | $76.73 Million | 1.03x | 10.35x |
Competitor Companies of 002907 by Market Capitalization
Companies near Chongqing Pharscin Pharmaceutical Co Ltd in the global market cap rankings as of November 4, 2026. Also see Chongqing Pharscin Pharmaceutical Co Ltd asset portfolio for a full breakdown of the balance sheet.
Key companies related to Chongqing Pharscin Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Chongqing Pharscin Pharmaceutical Co Ltd (2017–2026)
Market capitalization of Chongqing Pharscin Pharmaceutical Co Ltd from 2017 to today. Between 2017 and today, Chongqing Pharscin Pharmaceutical Co Ltd's market cap moved from $1.12 Billion to $ 788.90 Million, with a yearly change of 8.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥788.90 Million | -12.83% |
| 2025 | CN¥905.00 Million | +13.92% |
| 2024 | CN¥794.40 Million | -15.30% |
| 2023 | CN¥937.89 Million | -23.77% |
| 2022 | CN¥1.23 Billion | +13.23% |
| 2021 | CN¥1.09 Billion | +34.78% |
| 2020 | CN¥806.21 Million | -19.25% |
| 2019 | CN¥998.34 Million | -11.42% |
| 2018 | CN¥1.13 Billion | +0.26% |
| 2017 | CN¥1.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Chongqing Pharscin Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $788.90 Million USD |
| MoneyControl | $788.90 Million USD |
| MarketWatch | $788.90 Million USD |
| marketcap.company | $788.90 Million USD |
| Reuters | $788.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chongqing Pharscin Pharmaceutical Co Ltd
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, soft capsules, powder injections, freeze-dried powders, injections, chemical raw materials, and small volume injections. It provides its products for the treatment of CNS, digestion, otolaryngology, oncology, cardiovascular, an… Read more